904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 32; pp. S803 - S804
Main Authors Ho, A.L., Bowles, D.W., Even, C., Hao, D., Kang, H., Metcalf, R., Muzaffar, J., Oliva, M., Perez, C.A., Popovtzer, A., Rodriguez, C.P., Stemmer, S.M., Van Herpen, C.M., Winquist, E., Wirth, L.J., Worden, F.P., Xia, B., Gordon, G., Gordon, G.B., Ferrarotto, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2021
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.1314